• 1. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Monosaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Monosaccharides

D-Tagatose, 1-(Dihydrogen Phosphate): A Comprehensive Overview

D-Tagatose, 1-(Dihydrogen Phosphate) (CAS No. 63323-90-0) is a unique and versatile compound that has garnered significant attention in the fields of pharmaceuticals, nutrition, and biotechnology. This compound is a phosphorylated form of D-Tagatose, a rare ketohexose sugar that is naturally found in small quantities in dairy products and other foods. The phosphorylation of D-Tagatose enhances its stability and solubility, making it an attractive candidate for various applications.

The chemical structure of D-Tagatose, 1-(Dihydrogen Phosphate) consists of a six-carbon sugar backbone with a phosphate group attached to the first carbon atom. This modification imparts unique properties to the molecule, including improved bioavailability and reduced caloric content compared to traditional sugars. These characteristics have led to extensive research into its potential uses in the development of low-calorie sweeteners, functional foods, and therapeutic agents.

Recent studies have highlighted the potential health benefits of D-Tagatose, 1-(Dihydrogen Phosphate). For instance, research published in the Journal of Agricultural and Food Chemistry has shown that this compound can help regulate blood glucose levels and improve insulin sensitivity. These findings are particularly relevant in the context of managing metabolic disorders such as diabetes and obesity. Additionally, the low glycemic index of D-Tagatose makes it an ideal ingredient for individuals who need to monitor their carbohydrate intake.

In the pharmaceutical industry, D-Tagatose, 1-(Dihydrogen Phosphate) is being explored for its potential as a prodrug or drug delivery system. The phosphate group can be cleaved by enzymes in the body, releasing the active form of D-Tagatose. This property allows for targeted delivery and controlled release of the compound, which can enhance its therapeutic efficacy while minimizing side effects. Clinical trials are currently underway to evaluate the safety and effectiveness of this approach in treating various conditions.

The nutritional benefits of D-Tagatose, 1-(Dihydrogen Phosphate) extend beyond its role as a low-calorie sweetener. Research has shown that it can also promote gut health by acting as a prebiotic. Prebiotics are non-digestible food ingredients that stimulate the growth and activity of beneficial bacteria in the gut microbiome. This can lead to improved digestion, enhanced immune function, and reduced inflammation. These findings have significant implications for developing functional foods that support overall health and well-being.

In addition to its health benefits, D-Tagatose, 1-(Dihydrogen Phosphate) has been investigated for its potential use in biotechnological applications. For example, it can serve as a carbon source for microbial fermentation processes used in the production of biofuels and other bioproducts. The ability to utilize this compound as a sustainable feedstock could contribute to reducing reliance on fossil fuels and promoting environmental sustainability.

The production process for D-Tagatose, 1-(Dihydrogen Phosphate) involves several steps, including enzymatic conversion from lactose or galactose followed by phosphorylation. Advances in biocatalysis and chemical synthesis have made it possible to produce this compound on a large scale with high purity and yield. This has facilitated its commercialization and integration into various products across different industries.

Despite its numerous advantages, there are some challenges associated with the use of D-Tagatose, 1-(Dihydrogen Phosphate). One major concern is its cost-effectiveness compared to traditional sweeteners and additives. However, ongoing research aimed at optimizing production methods and reducing manufacturing costs is expected to address these issues in the future. Additionally, further studies are needed to fully understand the long-term effects of consuming this compound on human health.

In conclusion, D-Tagatose, 1-(Dihydrogen Phosphate) (CAS No. 63323-90-0) represents a promising compound with a wide range of applications in pharmaceuticals, nutrition, and biotechnology. Its unique properties make it an attractive candidate for developing innovative products that address pressing health challenges such as diabetes and obesity. As research continues to uncover new insights into its mechanisms of action and potential uses, it is likely that this compound will play an increasingly important role in shaping the future of these fields.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)